Table 3.
Interventional clinical trials investigating the antineoplastic effects of Bromodomain and Extra Terminal (BET) inhibitors as single agent or in combination with other Food and Drug Administration (FDA)-approved drugs.
| BET Inhibitors | Intervention | Status | Condition | Study Type | Phase | NCT Number |
|---|---|---|---|---|---|---|
| I-BET762 (GSK525762) | GSK525762 + FULVESTRANT vs. GSK525762 + PLACEBO | RECRUITING | ER and/or PR-positive/HER2-Negative Advanced or Metastatic Breast Cancer | INTERVENTIONAL | II | NCT02964507 |
| GSK525762 + ABIRATERONE/ENZALUTAMIDE +PREDNISONE | RECRUITING | Castration-resistant Prostate Cancer | INTERVENTIONAL | I | NCT03150056 | |
| GSK525762 monotherapy | RECRUITING | Relapsed Refractory Hematologic Malignancies | INTERVENTIONAL | I | NCT01943851 | |
| GSK525762 monotherapy | ACTIVE | NUT Midline Carcinoma | INTERVENTIONAL | I | NCT03702036 | |
| MK-8628 monotherapy | COMPLETED | Advanced Solid Tumor | INTERVENTIONAL | I | NCT02259114 | |
| MK-8628 monotherapy | COMPLETED | Hematologic Malignancies | INTERVENTIONAL | I | NCT01713582 | |
| MK-8628 monotherapy | ACTIVE | Hematologic Malignancies | INTERVENTIONAL | I | NCT02698189 | |
| FT-1101 | FT-1101 + AZACITIDINE vs. FT-1101 + PLACEBO | RECRUITING | Hematologic Malignancies | INTERVENTIONAL | I | NCT02543879 |
| CPI-0610 | CPI-0610 + Ruxolitinib vs. CPI-0610 + PLACEBO | RECRUITING | Hematologic Malignancies | INTERVENTIONAL | I-II | NCT02158858 |
| CPI-0610 monotherapy | COMPLETED | Multiple Myeloma | INTERVENTIONAL | I | NCT02157636 | |
| CPI-0610 monotherapy | ACTIVE | Lymphoma | INTERVENTIONAL | I | NCT01949883 | |
| INCB054329 | INCB054329 monotherapy | COMPLETED | Advanced Solid Tumors and Hematologic Malignancies | INTERVENTIONAL | I-II | NCT02431260 |
| RO6870810 | RO6870810 + Atezolizumab vs. RO6870810 + PLACEBO | RECRUITING | Advanced Ovarian Cancer and TNBC | INTERVENTIONAL | I | NCT03292172 |
| RO6870810 and VENETOCLAX + RITUXIMAB vs. RO6870810 and VENETOCLAX + PLACEBO | RECRUITING | DLBCL | INTERVENTIONAL | I | NCT03255096 | |
| GSK2820151 | GSK2820151 monotherapy | ACTIVE | Advanced or Recurrent Solid Tumors | INTERVENTIONAL | I | NCT02630251 |
| ZEN003694 | ZEN003694 monotherapy | COMPLETED | Metastatic Castration-resistant Prostate Cancer | INTERVENTIONAL | I | NCT02705469 |
| ZEN003694 + ENZALUTAMIDE vs. ZEN003694 + PLACEBO | RECRUITING | Metastatic Castration-resistant Prostate Cancer | INTERVENTIONAL | I-II | NCT02711956 | |
| BMS-986158 | BMS-986158 and NIVOLUMAB | RECRUITING | Advanced Tumors | INTERVENTIONAL | I-II | NCT02419417 |
| ABBV-075 | ABBV-075 and VENETOCLAX | RECRUITING | Solid Tumors | INTERVENTIONAL | I | NCT02391480 |
| GS-5829 | GS-5829 + ENZALUTAMIDE vs. GS-5829 + PLACEBO | ACTIVE | Metastatic Castration-resistant Prostate Cancer | INTERVENTIONAL | I-II | NCT02607228 |
| GS-5829 + FULVESTRANT vs. GS-5829 + EXEMESTANE | COMPLETED | Advanced Solid Tumors and Lymphomas | INTERVENTIONAL | I | NCT02392611 | |
| PLX51107 | PLX51107 monotherapy | RECRUITING | Advanced Solid Tumors and Hematologic Malignancies | INTERVENTIONAL | I | NCT02683395 |
FULVESTRANT, anti-estrogen receptor; ABIROTERONE, ENZALUTAMIDE, anti-androgen; PREDNISONE, corticosteroid; AZACITADINE, DNA methylation inhibitor; RUXOLITINIB, JAK2 inhibitor; ATEZOLIZUMAB, anti-PD-L1 monoclonal antibody; VENETOCLAX, BCL2 inhibitor; RITUXIMAB, anti-CD20 monoclonal antibody; NIVOLUMAB, anti-PD1 monoclonal antibody; EXEMESTONE, anti-estrogen. BC, breast cancer; CR-PC, castration-resistant prostate cancer; NMC, NUT midline carcinoma; NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer; GBM, glioblastoma multiforme; MM; multiple myeloma; OC, ovarian cancer; DLBCL, diffuse large B-cell lymphoma.